In conclusion, we have identified a high frequency of deletion in the CDKN2A gene in primary melanoma tumors, which supports previous evidence that gene deletion is the major mode of inactivation of CDKN2A and bypass of cell cycle control required for proliferation and progression to metastatic disease in malignant melanoma. This evidence concerns the gene CDKN2A and metastatic neoplasm.